AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19135567 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (EE/DSG and EE/CMA)
Number of subjects: 28
Study 17386385 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of technetium 99m sestamibi at 30 to 60 minutes after balloon inflation (group 1, n = 20)
Number of subjects: 30
Study 17386385 — intervention group
Group type: COMPARATOR
Intervention: Injection of technetium 99m sestamibi at 90 to 120 minutes after balloon inflation (group 2, n = 10)
Number of subjects: 30
Study 14734128 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2 g/day
Number of subjects: 30
Study 14734128 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 30
Study 11726454 — intervention group
Group type: EXPERIMENTAL
Intervention: IV midazolam
Number of subjects: 60
Study 11726454 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl plus midazolam
Number of subjects: 60
Study 11726454 — intervention group
Group type: EXPERIMENTAL
Intervention: No sedative
Number of subjects: 60
Study 11726454 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 60
Study 8989332 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (single intramuscular dose, maximum dose of 50 mg/kg)
Number of subjects: 484
Study 8989332 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (10 days of oral treatment, 8 mg of TMP and 40 mg of SMZ/kg/day in two divided doses)
Number of subjects: 484
Study 8989332 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 484
Study 8989332 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 484
Study 8516652 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cisapride
Number of subjects: 20
Study 8516652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3731687 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 10
Study 3731687 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem
Number of subjects: 10
Study 3731687 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine
Number of subjects: 10
Study 31820836 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based education (educational videos about cervical cancer and Pap smear test)
Number of subjects: 1290
Study 31820836 — intervention group
Group type: COMPARATOR
Intervention: Control group (no web-based education)
Number of subjects: 1290
Study 31820836 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1290
Study 31820836 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 1290
Study 31326117 — intervention group
Group type: EXPERIMENTAL
Intervention: Peek Acuity
Number of subjects: 111
Study 27749358 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR) training
Number of subjects: 17
Study 23849005 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacist's intervention (drug dosing adjustment service)
Number of subjects: 40
Study 22004351 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Head Start (EHS) program
Number of subjects: 3001
Study 19380288 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan
Number of subjects: 60
Study 19380288 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone
Number of subjects: 60
Study 16670361 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HT3 receptor antagonist (5‐HT3RA) plus dexamethasone
Number of subjects: 0
Study 16670361 — intervention group
Group type: COMPARATOR
Intervention: 5‐HT3 receptor antagonist (5‐HT3RA)
Number of subjects: 0
Study 16670361 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 0
Study 15248875 — intervention group
Group type: EXPERIMENTAL
Intervention: Astra Tech implants
Number of subjects: 66
Study 15248875 — intervention group
Group type: COMPARATOR
Intervention: Brånemark implants
Number of subjects: 66
Study 11422089 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metamizol
Number of subjects: 179
Study 11422089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 10437252 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) drugs for supporting healthy energy and removing blood stasis
Number of subjects: 32
Study 10437252 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 32
Study 7873465 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (ACE inhibitor)
Number of subjects: 0
Study 7873465 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapeutic regimens
Number of subjects: 0
Study 3061846 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymecycline therapy (300 mg b.i.d. for 14 days)
Number of subjects: 55
Study 3061846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 3061846 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymecycline therapy
Number of subjects: 55
Study 3061846 — intervention group
Group type: COMPARATOR
Intervention: Lymecycline therapy and Placebo
Number of subjects: 55
Study 29884735 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 181
Study 29884735 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic normothermia
Number of subjects: 181
Study 27050187 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 797
Study 27050187 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 797
Study 25155103 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS assistance
Number of subjects: 30
Study 25155103 — intervention group
Group type: COMPARATOR
Intervention: No CDS assistance
Number of subjects: 30
Study 21801330 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum
Number of subjects: 31
Study 21801330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 21262893 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy screener
Number of subjects: 4889
Study 21262893 — intervention group
Group type: EXPERIMENTAL
Intervention: Enumeration and pregnancy screening
Number of subjects: 4889
Study 21262893 — intervention group
Group type: EXPERIMENTAL
Intervention: Consent process
Number of subjects: 4889
Study 21262893 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-level variables
Number of subjects: 4889
Study 18163999 — intervention group
Group type: EXPERIMENTAL
Intervention: Coasting
Number of subjects: 0
Study 18163999 — intervention group
Group type: COMPARATOR
Intervention: Cryopreservation of all embryos
Number of subjects: 0
Study 16526560 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg TLP (Talampanel) administered orally in fasted and fed states.
Number of subjects: 28
Study 12517808 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg/m2)
Number of subjects: 336
Study 12517808 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (10 mg/m2)
Number of subjects: 336
Study 10644869 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination after one dose of GM-CSF (24 hours post-administration)
Number of subjects: 28
Study 10644869 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of hepatitis B vaccine after one dose of GM-CSF (24 hours post-administration)
Number of subjects: 28
Study 10644869 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccination alone (control for primary immunization)
Number of subjects: 28
Study 10644869 — intervention group
Group type: COMPARATOR
Intervention: Booster dose of hepatitis B vaccine alone (control for booster dose)
Number of subjects: 28
Study 8795443 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger arterial pressure (FINAP)
Number of subjects: 8
Study 2252161 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (IT) with an alginate-conjugated extract of D. pteronyssinus
Number of subjects: 33
Study 2252161 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 33
Study 6794308 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble aspirin daily for 6 weeks
Number of subjects: 100
Study 6794308 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aspirin)
Number of subjects: 100
Study 30359862 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfat dairy milk (NFM)
Number of subjects: 22
Study 30359862 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-fat dairy milk (FFM)
Number of subjects: 22
Study 30359862 — intervention group
Group type: COMPARATOR
Intervention: Glucose (GLU)
Number of subjects: 22
Study 30359862 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfat dairy milk (NFM) and Full-fat dairy milk (FFM)
Number of subjects: 22
Study 28401794 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radioiodine (1850 MBq)
Number of subjects: 278
Study 28401794 — intervention group
Group type: COMPARATOR
Intervention: High-dose radioiodine (3700 MBq)
Number of subjects: 278
Study 28401794 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 278
Study 24360978 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose soy isoflavone (300 mg/day)
Number of subjects: 431
Study 24360978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study 23786894 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5mg
Number of subjects: 51
Study 23786894 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10mg
Number of subjects: 51
Study 23786894 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20mg
Number of subjects: 51
Study 23786894 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA plus Rivaroxaban 5mg
Number of subjects: 51
Study 23786894 — intervention group
Group type: COMPARATOR
Intervention: ASA plus Clopidogrel
Number of subjects: 51
Study 23786894 — intervention group
Group type: COMPARATOR
Intervention: ASA alone
Number of subjects: 51
Study 21794791 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser intervention with girlase E11010, applied individually with six frequencies on seven anatomical zones
Number of subjects: 31
Study 21794791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 19366845 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 16 weeks
Number of subjects: 15
Study 19366845 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy BMI-matched women)
Number of subjects: 15
Study 19366845 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemic clamp
Number of subjects: 15
Study 17131283 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and clinical variables assessed early during hospitalization
Number of subjects: 163
Study 15295364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 921
Study 11089822 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiripentol
Number of subjects: 41
Study 11089822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 9573762 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg daily for 5 days a week)
Number of subjects: 52
Study 9573762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 7893931 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic compression of an upper limb
Number of subjects: 21
Study 7893931 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic compression of the lower limbs
Number of subjects: 21
Study 7893931 — intervention group
Group type: COMPARATOR
Intervention: Without elastic compression
Number of subjects: 21
Study 3141887 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g ceftriaxone
Number of subjects: 52
Study 3141887 — intervention group
Group type: COMPARATOR
Intervention: 2 g ceftriaxone
Number of subjects: 52
Study 29464504 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg/h of propofol (P2)
Number of subjects: 66
Study 29464504 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg/h of propofol (P1)
Number of subjects: 66
Study 29464504 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg/h of propofol (P0.5)
Number of subjects: 66
Study 29464504 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (P2, P1, P0.5)
Number of subjects: 66
Study 28762140 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap-assisted sigmoidoscopy
Number of subjects: 0
Study 28762140 — intervention group
Group type: COMPARATOR
Intervention: Non-cap-assisted sigmoidoscopy
Number of subjects: 0
Study 24424711 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg rimonabant
Number of subjects: 24
Study 24424711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 22754096 — intervention group
Group type: EXPERIMENTAL
Intervention: succinylcholine (1.0 mg/kg BW)
Number of subjects: 27
Study 22754096 — intervention group
Group type: EXPERIMENTAL
Intervention: rocuronium (0.5 mg/kg BW)
Number of subjects: 27
Study 22754096 — intervention group
Group type: COMPARATOR
Intervention: saline (15 mL)
Number of subjects: 27
Study 19924124 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's wort (300 mg t.i.d.)
Number of subjects: 12
Study 19924124 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (300 mg b.i.d.)
Number of subjects: 12
Study 19924124 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of St John's wort and ritonavir
Number of subjects: 12
Study 18515308 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous calcitriol
Number of subjects: 60
Study 18515308 — intervention group
Group type: COMPARATOR
Intervention: Daily orally administered calcitriol
Number of subjects: 60
Study 18515308 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (oral and intravenous calcitriol)
Number of subjects: 60
Study 15871845 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (120 mg)
Number of subjects: 10
Study 12678355 — intervention group
Group type: EXPERIMENTAL
Intervention: Single deep closed-suction drain
Number of subjects: 100
Study 12678355 — intervention group
Group type: COMPARATOR
Intervention: No drain
Number of subjects: 100
Study 10783996 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg pantoprazole
Number of subjects: 433
Study 10783996 — intervention group
Group type: COMPARATOR
Intervention: 40 mg pantoprazole
Number of subjects: 433
Study 8843129 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 8
Study 8843129 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (first half of therapy)
Number of subjects: 8
Study 8843129 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplements (second half of therapy)
Number of subjects: 8
Study 1609035 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (1.5-8.0 mg/day)
Number of subjects: 85
Study 1609035 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose reductions (10% twice weekly for 5 weeks to zero dose, then placebo for 2 weeks)
Number of subjects: 85
Study 1609035 — intervention group
Group type: COMPARATOR
Intervention: Stable dose for 7 weeks
Number of subjects: 85
Study 1609035 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation trial (n = 51)
Number of subjects: 85
Study 3086061 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg enteric-coated granules, once daily for nine days
Number of subjects: 12
Study 3086061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30220235 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib plus Sildenafil (nintedanib at a dose of 150 mg twice daily plus sildenafil at a dose of 20 mg three times daily)
Number of subjects: 274
Study 30220235 — intervention group
Group type: COMPARATOR
Intervention: Nintedanib (nintedanib at a dose of 150 mg twice daily plus placebo three times daily)
Number of subjects: 274
Study 30220235 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib plus Sildenafil
Number of subjects: 274
Study 30220235 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib plus Sildenafil and Nintedanib
Number of subjects: 274
Study 25898895 — intervention group
Group type: EXPERIMENTAL
Intervention: PMMA-based fixed dental prostheses (FDP)
Number of subjects: 27
Study 25898895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cantilevered FDPs
Number of subjects: 27
Study 25898895 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard design FDPs (n=37)
Number of subjects: 27
Study 25226602 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomy-supportive intervention program
Number of subjects: 27
Study 25226602 — intervention group
Group type: COMPARATOR
Intervention: Existing teaching style
Number of subjects: 27
Study 22926446 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB) alone
Number of subjects: 0
Study 22926446 — intervention group
Group type: COMPARATOR
Intervention: Axillary lymph node dissection (ALND)
Number of subjects: 0
Study 20435656 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 1409
Study 19126851 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent tracking task during stepping trials
Number of subjects: 0
Study 19126851 — intervention group
Group type: COMPARATOR
Intervention: No concurrent tracking task during stepping trials
Number of subjects: 0
Study 17072049 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (Bruce protocol exercise test)
Number of subjects: 44
Study 17072049 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no exercise)
Number of subjects: 44
Study 12967799 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 123
Study 12967799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ahmed glaucoma valve implant
Number of subjects: 123
Study 12967799 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 123
Study 10898322 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 500 mg three times daily (tid)
Number of subjects: 0
Study 10898322 — intervention group
Group type: COMPARATOR
Intervention: Famciclovir 125 mg, 250 mg, 500 mg three times daily (tid)
Number of subjects: 0
Study 10898322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9273203 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% histamine solution
Number of subjects: 71
Study 1735846 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous synthetic surfactant (Exosurf Neonatal)
Number of subjects: 32
Study 1735846 — intervention group
Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 32
Study 6877956 — intervention group
Group type: EXPERIMENTAL
Intervention: specific scanning strategies
Number of subjects: 52
Study 6877956 — intervention group
Group type: COMPARATOR
Intervention: word-matching exercises
Number of subjects: 52
Study 31433304 — intervention group
Group type: EXPERIMENTAL
Intervention: DOR 100 mg + TDF 300 mg (Study 1)
Number of subjects: 23
Study 31433304 — intervention group
Group type: EXPERIMENTAL
Intervention: DOR 100 mg + 3TC 300 mg + TDF 300 mg (Study 2)
Number of subjects: 23
Study 31433304 — intervention group
Group type: COMPARATOR
Intervention: 3TC 300 mg + TDF 300 mg (Study 2)
Number of subjects: 23
Study 29110567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg plaster
Number of subjects: 130
Study 29110567 — intervention group
Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 130
Study 27029350 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA) for AF
Number of subjects: 203
Study 27029350 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone (AMIO)
Number of subjects: 203
Study 27029350 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA)
Number of subjects: 203
Study 24594678 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg of LSD
Number of subjects: 12
Study 24594678 — intervention group
Group type: COMPARATOR
Intervention: 20 μg of LSD (with crossover to 200 μg after unmasking)
Number of subjects: 12
Study 22138521 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant multiple micronutrient (MMN) supplementation
Number of subjects: 58
Study 22138521 — intervention group
Group type: COMPARATOR
Intervention: Folic acid
Number of subjects: 58
Study 19562652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry (C) two times daily (C, C; n = 10 pregnant)
Number of subjects: 27
Study 19562652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry in the AM, then placebo (P) in the PM (C, P; n = 9 pregnant)
Number of subjects: 27
Study 19562652 — intervention group
Group type: COMPARATOR
Intervention: Placebo two times daily (P, P; n = 8 pregnant)
Number of subjects: 27
Study 19102746 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine tablets (Coartem)
Number of subjects: 245
Study 19102746 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine suspension (Co-artesiane)
Number of subjects: 245
Study 15480571 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate (2 g daily)
Number of subjects: 0
Study 11903272 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and systems strategies targeting rural primary-care physicians
Number of subjects: 2093
Study 9932992 — intervention group
Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy
Number of subjects: 22
Study 9932992 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser in situ keratomileusis
Number of subjects: 22
Study 7598056 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g alcohol/d for three menstrual cycles
Number of subjects: 18
Study 7598056 — intervention group
Group type: COMPARATOR
Intervention: Alcohol intake phase
Number of subjects: 18
Study 2115613 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose (HD) of 0.1 mg/sqm, three times a week
Number of subjects: 30
Study 2115613 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose (LD) of 0.01 mg/sqm, three times a week
Number of subjects: 30
Study 2115613 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant gamma‐interferon (r‐IFN‐gamma) therapy
Number of subjects: 30
Study 31060615 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg elemental iron and 2.8 mg folic acid
Number of subjects: 1959
Study 31060615 — intervention group
Group type: COMPARATOR
Intervention: Folic acid alone
Number of subjects: 1959
Study 28586713 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Internet-Based Cognitive Behavior Therapy (ICBT) for 8 weeks
Number of subjects: 156